Skip to content

Erasca, Inc. ERAS Net Investment in Lease

Net Investment in Lease at other companies

Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Tango Therapeutics logo
Tango TherapeuticsTNGX
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s net investment in lease?
Erasca, Inc. (ERAS) reported net investment in lease of $28.27M in Q1 2026.
How has Erasca, Inc.'s net investment in lease changed year-over-year?
Erasca, Inc.'s net investment in lease decreased by 10.3% year-over-year, from $31.53M to $28.27M.
What is the long-term trend for Erasca, Inc.'s net investment in lease?
Over 5 years (2020 to 2025), Erasca, Inc.'s net investment in lease has grown at a 67.1% compound annual growth rate (CAGR), from $2.23M to $29.03M.